124
Participants
Start Date
September 9, 2021
Primary Completion Date
June 23, 2023
Study Completion Date
June 23, 2023
Placebo
Pharmaceutical form: Tablet Route of administration: Oral
Rilzabrutinib
Pharmaceutical form: Tablet Route of administration: Oral
National Allergy and Asthma Research, LLC. Site Number : 8400007, North Charleston
Investigational Site Number : 2030002, Pilsen
Florida International Research Center Site Number : 8400002, Miami
Integrative Skin Care of MS/SKYCRNG Site Number : 8400011, Ridgeland
Skin Sciences, PLLC Site Number : 8400005, Louisville
DS Research of Kentucky, LLC Site Number : 8400004, Louisville
Investigational Site Number : 2760001, Bad Bentheim
Investigational Site Number : 2030003, Pardubice
Orion Clinical Research Site Number : 8400003, Austin
E.P.I.M.R.D dba Western Sky Research, Inc. Site Number : 8400009, El Paso
Asthma and Allergy Associates, PC Site Number : 8400008, Colorado Springs
Investigational Site Number : 2760002, Friedrichshafen
Investigational Site Number : 6160008, Chojnice
Antelope Valley Clinical Trials Site Number : 8400001, Northridge
Investigational Site Number : 1520004, Santiago
Investigational Site Number : 1520001, Santiago
Investigational Site Number : 1520002, Santiago
Investigational Site Number : 1240008, Red Deer
Investigational Site Number : 1240013, Greater Sudbury
Investigational Site Number : 1240001, London
Investigational Site Number : 1240002, Markham
Investigational Site Number : 1240011, Toronto
Investigational Site Number : 1240007, Toronto
Investigational Site Number : 1240004, Québec
Investigational Site Number : 2030004, Olomouc
Investigational Site Number : 2030001, Prague
Investigational Site Number : 5280001, Utrecht
Investigational Site Number : 6160001, Lodz
Investigational Site Number : 6160005, Gdansk
Investigational Site Number : 6160002, Lodz
Investigational Site Number : 6160004, Warsaw
Lead Sponsor
Sanofi
INDUSTRY